Table of contents
Kinpeygo is a medicine used to treat adults with primary immunoglobulin A nephropathy (IgAN) whose disease is at risk rapidly getting worse. IgAN is a disease where the kidneys gradually stop working and eventually fail, requiring patients to undergo dialysis or have a kidney transplant.
Kinpeygo is a ‘hybrid medicine’. It is similar to a ‘reference medicine’ containing the same active substance, but is used for a different disease and is given in a different way. The reference medicine for Kinpeygo is Entocort.
IgAN is rare, and Kinpeygo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here.
Kinpeygo : EPAR - Medicine overview (PDF/126.53 KB)
First published: 18/07/2022
Kinpeygo : EPAR - Risk-management-plan summary (PDF/104.58 KB)
First published: 18/07/2022
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.
Stada Arzneimittel AG
|Date of issue of marketing authorisation valid throughout the European Union||
23/11/2022 Kinpeygo - EMEA/H/C/005653 - IB/0002
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antidiarrheals, intestinal antiinflammatory / antiinfective agents
Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.